GlassScriptPhysician profile
Ashly Skaggs
NPI 1902511462
$6,936.88
in general payments reported to CMS, 2019-2025
22 companies · $2,753 in 2025
The $2,753 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,781 · 2024: $2,403 · 2025: $2,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,936.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,028.31 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $876.84 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $705.15 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $577.33 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $490.15 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $432.73 | 2023-2025 | Auvelity |
| Alkermes, INC. | $427.88 | 2023-2025 | Aristada, Lybalvi |
| Corium, LLC | $424.73 | 2023-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $343.01 | 2023-2025 | Fanapt, Hetlioz |
| Biogen, INC. | $304.90 | 2024-2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $271.49 | 2023-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $269.12 | 2023-2025 | Caplyta |
| Lundbeck LLC | $246.02 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $182.63 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $148.46 | 2023-2025 | Xelstrym, Secuado |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $50.81 | 2023-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $39.63 | 2024 | |
| Collegium Pharmaceutical, INC. | $35.11 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $30.58 | 2023 | Quviviq |
| Indivior INC. | $20.36 | 2023 | Perseris |
| Janssen Biotech, INC. | $16.19 | 2023 | |
| Supernus Pharmaceuticals, INC. | $15.45 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashly Skaggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.